Answers are grounded in this paper and cite their sources.
ARASENS was a randomized, double-blind, phase 3 trial comparing darolutamide + docetaxel + androgen deprivation therapy (ADT) with placebo + docetaxel + ADT in patients with metastatic hormone-sensitive prostate cancer (mHSPC).
No takes yet. Share an insight, caveat, or question.
Morgans et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: